Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

NCT01273948 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Bavituximab
DRUG: Pegylated interferon (PEG-IFN)

Sponsor

Peregrine Pharmaceuticals